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1. Introduction
Cancer is a group of diseases identified by unmanageable 
growth and expansion of abnormal cells that cause life 
risk leading to death if not managed. The phenomenon 
of conversion of a normal cell to a tumor cell is called 
malignancy (Seyfried & Huysentruyt, 2013). Programmed 
cell death (APOPTOSIS) in healthy tissues is restored by 
defiant cell growth in cancer cells (Elmore, 2007). The 
most frequent cancers in the globe are lung cancer, skin 
cancer, colorectal cancer, bladder cancer, and breast cancer. 
Globally it is surveyed that, about 1 in 6 deaths is due to 
cancer (World Health Organization, 2018). In India, breast 
cancer is the leading cause of cancer-related mortality in 
women causing 13% death around the globe (World Health 
Organization, October 2010).
Breast cancer can be said as the malignant tumor (a 
tumor occupy other tissues and spread or metastasize into 
other parts of the body) that develops in the cells of the 
breast. It is the most common cancer form, which has high 
morbidity and mortality, and it is second to lung cancer. 
Despite the standard treatment, the significance of the disease 
increases year after year. It can occur in both male and female, 
but male breast cancer is rare (Palanisamy, 2017).  Cancer 
of the breast is ranked number one in Indian women with a 
rate of 25.8 per 100,000 women and mortality rate of 12.7 
per 100,000 women (Malvia, 2017). The Indian Medical 
Research Council estimated that India could record more 
than 17 fresh cancer instances and 8 lakh disease fatalities by 
2020 (India today, May 2016). An article by Times of India 
mentioned that, according to statistics in 2017, in India, 
cancer has been reported at 0.7 million, representing females, 
after China and the US as the third largest instances of cancer. 
In India, breast cancer is the most known cancer in women, 
which reports 14% of all other cancers in women (Bray et al., 
2014). In 2018, 1,62,468 new cases and 87,090 death cases 
of breast cancer were registered in India. 
When cells in the breast start to increase uncontrollably, 
it causes breast cancer. Factors evolving breast cancer are 
early menarche, late menopause, genetic causes, family 
history, race, ethnicity, drinking alcohol, having dense breast 
tissue, overweight or obese. The hormones oestrogens and 
progesterone are of essential importance in the prognosis 
of this disease. Hormone balance disorder of the body is 
accountable for the progression of this disease. Nearly all 
breast cancer cells show the initial appearance of receptors 
for these hormones. In some cancer cells, Human Epidermal 
Growth Factor Receptor 2 (HER2) receptors are sometimes 
spotted. Hormone-targeted therapy results depend on the 
nature of these receptors. Some breast cancer cells fail to 
disclose any types of receptors interaction, which are termed 
as triple negative cancer. 
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The stage and prognosis of cancer cells can be identified 
by a staining process called immunohistochemistry and a 
scoring system called NPI is appointed for this process. The 
Nottingham prognostic index (NPI) is based on the factors 
like tumor size, lymph node stage, and tumor grade can spot 
the advancement and aggressiveness of cancer. This NPI 
system is built on the differentiation of cancer cells that is 
between Well-differentiated cancer cells (grows slowly) and 
poorly differentiated cancer cells (metastasize rapidly). The 
scoring system is like: 
• 3–5 points: Grade I - Well differentiated
• 6–7 points: Grade II - Moderately differentiated 
• 8–9 points: Grade III - Poorly differentiated (Adhikary, 
2018)
Most breast cancers are diagnosed as small tumors within 
a range less than or equal to 2cm. It mostly gets diagnosed 
at early stages. It is evaluated that 5-10% of cancer is due 
to genetic defects that are inherited from family (Reeder & 
Vogel, 2008). 70,218 mortality cases of women who had 
breast cancer were reported in 2012 with the mortality rate 
of 12.7 per lac population, thus categorizing it as number 
one killer in women (Peng et al., 2009). One in seven women 
will be likely to develop breast cancer in the course of their 
lifetime. The prevalence of this disease in women older than 
90 years of age is lesser [10]. Breast cancer is commonly 
identified by sure signs and symptoms or screening tests that 
are helpful in the diagnosis of the disease and its degree of 
spread [8]. 
Management of breast cancer depends upon various 
stages of cancer. There are a number of treatment regimens 
which got well known over the past decades are chemotherapy, 
radiotherapy and tele-therapy, surgery and hormonal 
therapy (Shalini et al., 2010) and the anticancer drugs like 
5-fluorouracil, epirubicin, doxorubicin, cyclophosphamide, 
docetaxel/paclitaxel, carboplatin and antiestrogens (raloxifene 
or tamoxifen) used for the treatment of breast cancer (Karen 
et al., 2002). Tamoxifen is a specific modulator of the 
estrogen receptor being used since past three decades for 
the treatment of breast whereas selective estrogen receptor 
down regulators (SERDs) drugs like letrozole, anastrozole 
and exemestane are used to inhibit aromatase enzyme for 
producing estrogens for the treatment of breast cancer. 
The  most  frequently  used  therapy of breast cancer is the 
anthracyclines class of drugs, Epirubicin, and doxorubicin 
(Hum et al., 2016). The therapy has been modernized over 
the past decades, but still the mortality rate of patients is 
increasing day by day. Improper use of drugs can be hazardous 
to patients (Manichavasagam et al. 2017). In clinical practice, 
nonsensical prescriptions of drugs are common. The cost of 
the use of the nonsensical drug is enormous in the name of 
both inadequate stock and adverse clinical outcome of the 
treatments which can have risks but no clinical benefits. Use 
of multiple drugs side by side, which is commonly known 
as polypharmacy has been seen linked with adverse drug 
reactions, medication errors, and drug-drug interaction. 
Treatment with more than three drugs usually gets cases of 
a drug interaction. Hence, this can be another problem for 
mortality (Sjoqvist & Birkettm, 2003). 
Another problem, which can be considered as 
significant, is barriers between physicians and patients 
to the therapy - lack of confidence in physicians for 
identifying appropriate high-risk patients. There are 
specific tools which had never been used for identifying 
suitable candidates for preventive therapy (Pentareddy et 
al., 2015; Kanwal & Gupta 2012). Lack of knowledge, 
limited training in risk counseling, having worries about 
the medications side effects, lack of evidence, etc. are some 
barriers of the physicians. Fear of having side effects, high 
treatment cost, beliefs/concerns about the medications, 
confusion between chemotherapy and chemoprevention, 
having little or no knowledge about the disease are some 
barriers at the patient side. These factors lead to a higher 
mortality rate in patients with breast cancer (Park, 2015; 
Feuer et al., 1993). Therefore, this review aimed to 
determine the perceived insights and barriers to treatment 
of breast cancer. 
2. Etiology of Breast Cancer
The possibilities of getting breast cancer can swiftly 
increase with age through premenopausal and steadily 
increase through post-menopausal in life (Franca et al., 
2012). The probability of having a risk of breast cancer 
grows with age but are seen rare before the age of 20 years 
(McPherson et al., 2003). Having cancer in one breast can 
surely increase the probability of having cancer in another 
breast by four times whereas patients having a history 
of any ovarian, endometrial or colon cancer increase the 
possibility of 1–2 times for developing breast carcinoma 
(Kelsey & Bernstein, 1996). Having a benign tumor in the 
breasts can increase the likelihood of having breast cancer 
by becoming malignant (Jacobs et al., 1999). The causes of 
breast cancer are:
• Obese women after menopause can have a high risk 
of getting breast cancer as the fatty tissues increases 
producing a hormone (oestrogen/progesterone).
• Scarcity of exposure to the sun as well as having vitamin 
D deficiency is thought to be the primary cause of 
breast cancer (Alco et al., 2014).
• Women having a family history of breast cancer are 
2-4 times more prone to getting breast cancer. Mother, 
daughter, and sister fall on first-degree family members 
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who can be considered holding the threat whereas in 
case of having aunt or grandmother who has a history of 
breast cancer fall under second-degree family members 
will also increase the possibility of getting breast cancer. 
• Alcohol consumption also has a risk of getting breast 
cancer.
• Environmental factors can result in the development of 
breast cancer.
• Two genes, BRCA1 and BRCA2 increase the possibility 
of having Breast cancer. Among the joint investigation of 
22 researchers, 11 accepted that at 70 yrs. of age carrying 
BRCA1 gene, the chance of getting breast cancer is 65% 
and those carrying BRCA2 gene have 45% possibility of 
getting breast cancer (Nkondjock & Ghadirian, 2004). 
5-10% causing breast cancer can transfer from father or 
mother to the next generation in the family.
3. Associated Risks of Breast Cancer
Breast cancer, after affecting the breast, slowly grows to other 
areas of the body mostly affecting the lungs, liver, muscles, 
the bone, and lastly the brain. The associated risks of breast 
cancer are likely to be:
• Thickening of the breast tissue and itchy, dry and 
cracked skin around the breast.
• Improper treatment may lead to the malignant growth 
of lymph nodes that causes swelling in the arms.
• Malignant tumors can grow in lungs causing chronic 
cough and diseases like pneumonia or bronchitis. It can 
also cause difficulty in breathing and dyspnea.
• Spreading of cancer to the liver can cause severe 
swelling, edema, and jaundice and at very advanced 
stages can cause (if spread all over liver) liver cirrhosis 
leading to death.
• Later stages when it spreads to muscle and skeletal 
systems causing stiffness of joints, muscle pain and 
hence can cause risk of getting fractures, a problem in 
movement.
• At the last stage, it can spread to the brain affecting 
it, causing dementia, seizures, headache, difficulty in 
speaking, and even blindness.
Other effects to be likely can be loss of appetitive, sudden 
weight loss, feeling extremely tired, and so on (Kristeen, 2018). 
4. Clinical Presentation of Breast Cancer
Some of the symptoms of breast cancer are the development 
of:
• A new lump or mass, 
• Alteration in breast shape or size and having pain about 
all of the time in breast or armpit, 
• Rash on skin 
• Rash on surrounding the nipple, 
Other symptoms of breast cancer likely can involve:
• Swelling of the breast even if there is no sensation of a 
lump.
• Irritation in the skin (sometimes orange peel like).
• Pain in the breast or nipple.
• Reddening or inwards turning of the nipple.
• Scaling and thickening of breasts.
• Fluids are releasing other than breast milk from breasts.
Breast cancer typically is diagnosed by medical imaging, 
screening tests like mammograms, breast ultrasound, 
breast MRI scans and is naturally confirmed by doing a 
biopsy and other techniques that can help in detecting 
breast cancer in its early stages (Kanwal & Gupta 2012). 
It’s better to get to know about the symptoms of breast 
cancer as well as detecting breast cancer as early as possible, 
can help it for getting better treatment.
5. Pathophysiology
The breast is a complex tubulo-alveolar organ secured 
within an asymmetrical connective tissue (Stingl et al., 
2005). Starting from pregnancy to dementia period; the 
breast comes across chains of conversion. The atypical breast 
comprises of a stratified epithelium cell which contains two 
different cells that are myoepithelial and epithelial and are 
surrounded by a basement membrane and fastened within a 
pattern of blood vessels, stromal and lymphatic cells (Stingl 
et al., 2006). The cause of the cellular diversion in breast 
disorders depends on the prime development process of 
the breast. This diversion can be caused due to neoplastic 
alteration in myoepithelial or epithelial cells or from stem 
cell that can have the potential to evolve into myoepithelial 
or epithelial cells (Gusterson et al., 1982). As stated by the 
oncology of breast cancer, it is said that the neoplastic cells 
are different than the healthy cells present in the body.
The healthy cells present in our body have restricted 
growth or procedure to maintain the organization and 
activity of tissues whereas cancerous cells without any help 
of external spur do have a lengthy and chronic extension 
(Evan & Vousden, 2001). There are a lot of causes that can 
raise the malignant tumors to evolve into breast cancer. All 
the factors are demonstrated below through a flowchart. 
Two pathways, The Ras/Raf/Mitogen-activated protein 
kinase (MEK)/ extracellular-signal-regulated kinase (ERK) 
pathway and phosphoinositide 3-kinase/ Protein Kinase B 
(P13K/AKT) pathway protect healthy cells from cell suicide, 
but during mutation (transformation), these cells are not able 
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to commit suicide when not required and therefore develops 
into cancer (Cavalieri et al., 2006). This also happens when 
there is an excess articulation of leptinin breast adipose 
tissue, causing the growth of cancer cells (Jarde et al., 2011). 
Enzyme telomerase rejects the chromosomal shortening 
allowing replication of cells (Hanahan & Weinberg, 2000). 
From angiogenesis, tumor cells get nutrition and oxygen 
(Jain, 2005). 
Cancer cells have to interrupt their boundaries and can 
enter into the blood lymphatic tissues or other tissues of 
the body to construct secondary tumour (Fig.1.) (Gupta & 
Massagué, 2006).
Figure 1: Pathophysiology of Breast Cancer
6. Stages of Breast Cancer
There are several stages of breast cancer, which depends 
upon the type and size of the tumor as well as depends upon 
the area invaded by the tissue cells in the breast (Heim et 
al., 1997).
There are five stages of breast cancer:
Stage 0: This stage is known as non-invasive stage of the 
tumor. It contains both cancerous and non-cancerous tumor 
cells that develop at any part of the breast, but there is no 
confirmation of the tumor spreading to surrounding tissues 
or that area. Ductal cell carcinoma in situ (DCIS) is an 
example of stage 0 breast cancer (Bednarek at al., 1997).
Stage I: This stage is also known as Invasive Breast 
Carcinoma. There are two categories of this stage- 1A and 
1B. At 1A stage, the tumor size can be up to 2cm, and no 
lymph nodes are involved here. At 1B stage, tumor size 
larger than 0.2 mm and lymph nodes are involved (Segal 
et al., 2001).
Stage II: There are two categories of this stage- 2A and 2B. 
In 2A, tumor size varies between 2cm to 5cm and is detected 
naturally in axillary lymph nodes or sentinel lymph nodes 
but not detected in breasts. In 2B, tumor size can be more 
than 5cm but are not detected in the axillary lymph nodes 
(Moran et al., 2014).
Stage III: There are three categories of this stage- 3A, 3B, 
and 3C. In 3A, tumors can invade up to 4-9 axillaries or 
sentinel lymph nodes but not detected in the breast. In stage 
3B, it is known as inflammatory breast cancer as it causes 
red, warm and swollen skin of the breast and the tumors 
can be any size causing swelling or ulcers on the skin of the 
breast and can invade up to 9 axillaries or sentinel lymph 
nodes. In Stage 3C, tumor invasion can be up to 10 or more 
axillaries lymph nodes and also lymph nodes above or below 
the clavicle (Jacquillat et al., 1990).
Stage IV: This is the last stage and the advanced and 
metastatic stage of cancer. In this, the tumour spreads 
to other areas of the body like lungs, liver or brain, etc. 
(Neuman et al., 2010).
7. Types of Breast Cancer
Breast cancer is divided into six different classes. They are 
classified as follows:
Non-Invasive Breast Cancer: This type of cancer does not 
expand far from the place where it is situated in the lobules 
or ducts (West et al., 2017). Ductal carcinoma in situ is 
an example ofnon-invasive breast cancer. Development of 
atypical cells inside the milk ducts can lead to the formation 
of Ductal Carcinoma, but does not expand to the presence 
of tissue or external areas as it is “in-situ” meaning “in place” 
but can develop into invasive breast cancer if not treated 
(Posner & Wolmark, 1992). Under this class, it is divided 
into two types:
•	 Lobular-Carcinoma In-Situ: They are also known as 
non-invasive breast cancer that grows in the breast 
lobules (Inoue et al., 2017) that do not grow outside 
the breast lobules (Clauser et al., 2016).
•	 Ductal Carcinoma In-Situ: It is a common type of non-
invasive breast cancer which grows in the breast duct 
(milk ducts). Ductal comedocarcinoma is an example 
of this type of cancer (Nakhlis & Morrow, 2003).
Invasive Breast Cancer: Another name of invasive breast 
cancer is metastatic breast cancer (Stevanovic et al., 2006). 
When cells grow in the lobules or milk ducts and break 
into the breast tissue, it occurs into invasive breast cancer 
(Harris et al., 2016). These cells can proceed from breasts 
to different areas of the body between the immune system 
and systemic circulation (Ziperstein et al., 2016). This 
type of cancer mostly occurs in the female population, 
and they can spread to other parts of the body, even 
if when the tumor is small in size (Prabhakaran et al., 
2017). These cells can expand to the brain, lungs, liver, 
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and bones, causing cancer (Page et al., 2017). Invasive 
breast cancer is divided into five types:
•	 Infiltrating Lobular Carcinoma: This type of cancer 
develops from the lobules of the breast then gets spread 
to other parts of the body (Arpino et al., 2004).
•	 Infiltrating Ductal Carcinoma: This type of invasive 
breast cancer develops from the milk ducts of the breast 
and spreads to duct wall by saturating the fatty tissues 
of the breast and spreading to other areas of the body 
(Somiari et al., 2003).
•	 Medullary Carcinoma: it’s a type of invasive breast 
cancer that forms a wall between healthy tissue and 
medullary tissue hence separating each other (Mateo et 
al., 2017).
•	 Mucinous Carcinoma: Also known as colloid carcinoma 
and it’s very uncommon and is produced by the cancer 
cells that form mucus (Anuradha & Lakshmi, 2017).
•	 Tubular Carcinoma: They are a specific type of invasive 
breast cancer, and generally, females having tubular 
carcinoma have better hopes than females having another 
kind of invasive breast cancer (Priya & Prasaad, 2017).
Inflammatory Breast Cancer: It is a type of breast cancer 
that is very abnormal and rapidly arising. Here the cancer 
cells obstruct the lymph vessels and channels of the 
breast skin leading to swelling of breasts with prominent 
hollow ridges (Joglekar-Javadekar, 2017). Treatments like 
radiation therapy, surgery, chemotherapy, and imaging 
are done through proper observation. Early reporting 
can help in the use of adjuvant chemotherapy or loco-
regional treatment like surgery or radiation can cause fast 
improvement in the disease (Cariati et al., 2005).
Paget’s disease: It’s atypical breast cancer that causes change 
to the nipple of the breast that can comprise of red rashes 
(itchy) on the nipple, bleeding or fluid discharge from the 
nipple, a lump in breasts, conversion in nipple shape, etc. 
(Errichetti et al., 2017). It affects only one breast most of 
the time and is both common in men and women. A punch 
biopsy is used to diagnose Paget’s disease (Merrill et al., 
2017).
Phyllodes Tumor: It is a rare kind of breast cancer that 
grows in the connective of the breast, which can be benign 
or malignant and can be removed by surgery (Sera et al., 
2017). At least ten females die each year in the USA due to 
this type of cancer (Nozad et al., 2017).
Triple-Negative Breast Cancer: This is a devastating 
heterogeneous disorder that mostly seen in premenopausal 
females. Triple negative breast cancer caused due to deficiency 
of three receptors, which are progesterone receptor, human 
epidermal growth factor II, and estrogen receptor (Liedtke 
et al., 2008).
8. General Treatment and Management of 
Breast Cancer
Breast cancer is commonly treated with the combination 
of surgery, radiation therapy, chemotherapy, hormonal 
therapy and targeted therapy, which is done for reducing 
the size of the tumor and spread of the tumor (National 
Cancer Institute, 2012). People at an advanced stage of 
breast cancer are given palliative care. Pain and symptomatic 
treatment are an essential part of this care. The survival 
rate of cancer depends upon the type of cancer and stage 
of cancer (Murthy et al., 2011). Chemotherapy is a vital 
treatment part of the management of cancer. Chemotherapy 
alone or in combination with radiotherapy or surgery has 
given effective and curative results (Longo, 2012). These 
treatments are highly complex and are associated with a lot 
of adverse effects. In a breast cancer study, the incidence 
of adverse drug reactions (ADRs) in patients undergoing 
chemotherapy was seen at 39.1% (Chopra et al., 2016).
In a study in Taiwan on breast cancer patients, the 
traditional way of treatment was done. Here, Chinese herbal 
products containing dang-qui was prescribed to breast 
cancer patients. Dang-qui (Angelica sinensis radix) has a 
long history of its use in traditional Chinese pharmacopeia 
since 1590 AD by Shi-Zhen Li written in classical Chinese 
text named Ben Cao Gang Mu, Compendium of Materia 
Medica. Many women with breast cancer use alternative 
medicine, which includes herbs, vitamins, homeopathy, 
and Chinese herbal products (CHPs) to reduce symptoms 
of breast cancer. In Japan, South Korea, China, and Taiwan 
have a history of use of traditional Chinese medicine (TCM) 
by medicine practitioners (Lai, 2012).
In the modern treatment of breast cancer, treatment 
depends upon stages of breast cancer. In early breast cancer, 
Local, regional therapy is done where surgery is done to 
cure breast cancer by removing the tumor. Lumpectomy 
and radiation therapy are also done in most breast cancer 
patients. Radiation therapy is used for the treatment of bone 
metastasis. Some require post-mastectomy radiation therapy, 
but naturally, they are used in locally advanced breast cancer. 
Simple or total mastectomy is the removal of the entire breast 
without cutting up underlying muscle or axillary nodes. A 
new procedure has been seen introduced in many centers 
in the United States, which involves lymphatic mapping 
and sentinel lymph node biopsy. Systemic adjuvant therapy 
consists of systemic therapy followed by local treatment 
(surgery or radiation) when it is not in the metastatic stage. 
Preoperative systemic therapy, also known as 
neoadjuvant therapy, is gaining popularity nowadays for both 
treatments of an early and advanced stage of breast cancer. It 
decreases the size of the tumor without the need for surgery. 
Common adjuvant chemotherapy combination regimens for 
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breast cancer used are AC (doxorubicin+cyclophosphamide) 
followed by paclitaxel, FAC (fluorouracil+doxorubicin+cyc
lophosphamide), CAF (cyclophosphamide+doxorubicin+
fluorouracil), TAC (docetaxel+doxorubicin+cyclophospha
mide), FEC (fluorouracil+epirubicin+cyclophosphamide), 
CMF (cyclophosphamide+methotrexate+fluorouracil), CEF 
(cyclophosphamide+epirubicin+fluorouracil). Metastatic 
single agent chemotherapy drugs are paclitaxel, docetaxel, 
capecitabine, gemcitabine, vinorelbine, and doxorubicin. 
Metastatic combination regimes are docetaxel+capecitabine, 
d oxo r u b i c i n + d o c e t a xe l ,  e p i r u b i c i n + d o c e t a xe l . 
Anthracyclines (doxorubicin and epirubicin) are referred 
to as the most active class of chemotherapy regimen in the 
treatment of metastatic breast cancer. Tamoxifen is used 
in hormonal therapy for the treatment of breast cancer. 
Aromatase inhibitors (anastrozole, letrozole), antiestrogens 
(tamoxifen), Selective Estrogen Receptor Degraders 
(fulvestrant), progestins, androgens, estrogens are some 
endocrine therapies used for the treatment of metastatic 
breast cancer. Cytotoxic therapy and Biologic therapy 
are other therapies for the treatment of breast cancer. 
Trastuzumab is a drug used in biologic therapy of breast 
cancer.
Recent Studies in Advancement and Current Clinical Approaches For The Treatment of Breast 
Cancer
TITLE SUMMARY
Drug prescription pattern of breast cancer 
patients in a tertiary care hospital in West 
Bengal: Cross-Sectional and questionnaire-
Based Study 
Here 28 Female patients diagnosed with breast carcinoma of different types 
and grades, with an average age of 51yrs (±10.5) ranging from 28 to 73 
years with an average weight of 55.3 kg (±8.68) ranging from 40 to 78 kg, 
and average body surface area (BSA) of 1.47m2 attending the Surgical OPD 
and Department of Radiology, were included in the study. In the study, the 
menopausal status of the patients was identified, and the drugs prescribed 
to the patients were evaluated. The study revealed 7(25%) patients were 
premenopausal, and 21(75%) patients were post-menopausal. The most 
common drugs used in the study were Cyclophosphamide(20%), followed 
by docetaxel(13%), doxorubicin(12%), 5-fluorouracil(12%), paclitaxel(9%), 
epirubicin(9%), tamoxifen(8%), letrozole(7%), trastuzumab(6%), and 
carboplatin(4%). Hence, the study tried to evaluate the epidemiological 
profile of the disease, the risk factors associated with them, and the treatment 
provided to these cancer patients (Adhikary et al., 2018).
Breast Cancer and Non-steroidal Anti-
Inflammatory Drugs: Prospective Resultsfrom 
the Women’s Health Initiative
This study analyzed data from the prospective cohort Women’s Health 
Initiative (WHI) Observational Study to observe the effects of aspirin, 
ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) on 
regular use on breast cancer risk and was outlined to label some vital causes 
of morbidity and mortality socially and geographically. 1392 cases of breast 
cancer were taken for the study. Women with a history of cancer were 
included, whereas women having no medical update or data were excluded. 
80,741 women were analyzed, among which only 1392 identified breast 
cancer were examined. It was seen that about 21% of women taking NSAIDs 
twice a week for 5yrs brought a decrease in risk of breast cancer, whereas 
women with the use of 10yrs brought o 28% decrease in breast cancer. 
Ibuprofen, if used for the long term can bring a reduction in the risk of 
having breast cancer by 49% were the same in the case of aspirin, only 21%. 
It was seen that regular use of medication like Aspirin or other NSAIDs is 
good against breast cancer (Harris et al., 2003).
Selective serotonin reuptake inhibitors and 
breast cancer
mortality in women receiving tamoxifen: a 
population-based cohort study
The study was conducted to distinguish whether some selective serotonin 
reuptake inhibitor (SSRI) antidepressants can reduce the effect of tamoxifen 
by preventing its bio-activation by cytochrome P450 2D6 (CYP2D6). When 
tamoxifen is needed to be given with an antidepressant, then preference needs 
to be given to antidepressants that present little or no inhibition of CYP2D6. 
Out of 24430 patients going through tamoxifen treatment for 13 years, 
7489 patients were given at least one antidepressant. Paroxetine was the most 
commonly given SSRI including next sertraline then citalopram, venlafaxine, 
fluoxetine and lastly fluvoxamine. 1074 women died during the treatment, 
among which 374 cause of death was due to breast cancer (Kelly et al., 2010).
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Use of liposomal doxorubicin for adjuvant 
chemotherapy of
breast cancer in clinical practice
This study speaks about the clinical application of liposomal doxorubicin in 
adjuvant chemotherapy of breast cancer and clarifies the therapeutic effects, side 
effects of PEGylated liposomal doxorubicin (PLD) and non-PLD (NPLD) in 
clinical research. It was seen at the end of the study that combined PLD regime 
have shown more significant therapeutic effect in the treatment of HER-
2positive and negative breast cancer. Combination with doxorubicin was seen 
asvital treatment therapy among the anthracyclines even they are essential for 
the treatment of breast cancer. PLD and NPLD both have been seen working 
effectively in the treatment of most of the stages of breast cancer (Zhao et al., 
2017).
Melatonin, a Full-Service Anti-Cancer Agent: 
Inhibition of Initiation, Progression, and 
Metastasis
This study said about the use of melatonin therapy with other traditional or 
usual cancer treatment therapies, which by exploratory results encouraged using 
melatonin by its advantages, which can improve the health of the patients. It 
was seen that melatonin reduced the amount of acute typical cell damage and 
also melatonin protects the heart from any damage due to chemotherapy. It was 
stated that melatonin is a non-toxic endogenously molecule that can be used for 
the benefit of chemotherapy treatments (Reiter et al., 2017).
Treatment Modification in Young Breast Cancer 
Patients
It is on the treatment modification in young breast cancer patients. This study 
deals with the need for particular contemplation in young women like new 
treatment modification in endocrine therapy and ovarian suppression, fertility 
protection, and family planning, and genetic counselling. Detecting breast 
cancer less than 36yrs of age will require genetic counselling and testing, even 
if there is no family history of breast or ovarian cancer. Amenorrhoea and 
elevated gonadotropins such as follicular stimulating hormone (FSH) are 
irresponsible markers of infertility in women who have taken chemotherapy 
(Scharl et al., 2016).
Palbociclib: A new hope in the treatment of 
breast cancer
In this study article, a new drug called Palbociclib was tested. It is a selective 
cyclin-dependent kinase (CDK) 4/6 inhibitor, which is a new drug, currently 
has the approval for the treatment of ER+ and HER2− breast cancer in Feb 
2015. 10 out of 37 patients were having a good result after giving four cycles 
of the drug at phase I. It was noted that 6 out of 37 have triple negative breast 
cancer, 2 out of 37 having HER2+ and 29 out of 37 having ER+/HER− 
breast cancer. Hence, a starting dose of palbociclib was given 125 mg per day 
for 21 days daily then after a leave of 7days the dose will be reduced to 100 
mg per day followed by at end dose it will be 75 mg per day. Grape juice was 
seen having food interaction of palbociclib (Palanisamy, 2017).
Neoadjuvant treatment of breast cancer- 
Clinical and research
Perspective
This study reveals about the new advancements made in neoadjuvant therapy 
where Two groups are mainly concentrated for neoadjuvant therapy, which 
includes, HER2 and triple negative breast cancer. Neoadjuvant therapy is 
used for reducing the size of a tumor to avoid mastectomy and the axilla to 
avoid axillary clearance so that it can be used to conduct sentinel node biopsy. 
The study was to improve the long term treatment outcome and to decrease 
the mortality rate. Anthracycline and taxane therapies are the conventional 
treatment regimen nowadays, and therefore, the primary aim of this study was 
to increase complete pathological response to improve the survival rates of 
breast cancer (Loibl et al., 2015).
nab-Paclitaxel dose and schedule in breast 
cancer
In this study, we get to know about the dose of nab-paclitaxel, which is 
accepted for breast cancer treatment. Even if combined therapy has been seen 
ascompetent, still single nab-paclitaxel treatment is better in an unselected 
patient population. There are always trials going on the combination therapy 
for knowing whether the patient with a more aggressive disease should be 
treated or not. There were a total of five trials of nab-paclitaxelin Metastatic 
Breast Cancer with 15 patient population. Dose for nab-paclitaxel was 
recommended 260 mg/m2. A patient going on treatment with nab-paclitaxel 
experienced less toxicity then patient going on the treatment of the same 
regimen but with the metastatic setting. Nab-paclitaxel combined with 
bevacizumab also seen effective in the treatment of metastatic breast cancer, 
and the treatment cost was seen feasible for patients (Martín, 2015).
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Eribulin in advanced breast cancer: safety,
efficacy and new perspectives
In this study, it is talked about the use of eribulin drug molecule in the treatment 
of advanced stage breast cancer. This study was done for comparing the clinical 
trial results with life and was concluded that it got satisfactory results in TNBC 
and also can be given with a lot of combined drugs without any toxicity. It 
is also seen to be helpful in the treatment of elderly patients. It is a synthetic 
compound derived from halichondrin B, which is a natural product formed 
from a marine sponge named Halichondria Okadai. Total of 1095 patient’s data 
was investigated. Eribulin showed greater efficacy and potency when given with 
other anticancer drugs like paclitaxel. When eribulin treated in MBC patients, 
it showed reoxygenation by increasing the tumor oxygen saturation (SO2) and 
suppressing the TGF-β1, which can cause an antiangiogenetic effect (Garrone et 
al., 2017).
Pertuzumab and breast cancer: another piece in
the anti-HER2 puzzle
The combination of pertuzumab with trastuzumab and docetaxel was 
approved by the FDA as first-line treatment for HER2-positive metastatic 
breast cancer, and also it is the first drug to be used in the neoadjuvant 
therapy by using a full pathological response as an endpoint in the Cleopatra 
trial. A dose of 420 mg iv for three weeks was considered. This combination 
of pertuzumab to trastuzumab enhanced neoadjuvant as well as metastatic 
treatment in HER2 positive breast cancer patients. New pertuzumab therapies 
or regimes are investigated for improving the toxic effects and efficacy of 
treatments in the future future (Gerratana et al., 2017).
Ribociclib for the treatment of advanced 
hormone receptor-positive, HER2- negative 
breast cancer
Ribociclib is a selective oral inhibitor of CDK4/6 which was known as 
LEE011 that was approved by the US FDA for first-line treatment of 
hormone-receptor-positive/HER 2-negative metastatic breast cancer after 
palbociclib. Neutropenia was the adverse effect seen. Hence, CDK4/6 
inhibitors are undergrowth and have been found to have a significant action 
regarding the chronification of meta static HR+/HER2- breast cancer. 
CDK4/6 inhibitors prevent the hyper-phos phorylation of pRB and stop 
the progression of the cancer cell cycle. A dose of 600 mg/day based on 
administrating three weeks on and then 7days off. Ribociclib, in combination 
with letrozole, was given in phase-I trails. Toxicities seen were neutropenia, 
nausea, vomiting, diarrhoea, and fatigue (López-Tarruella et al., 2017).
Docetaxel and cyclophosphamide as 
neoadjuvant chemotherapy
in HER2-negative primary breast cancer
This prospective study evaluates the efficacy of TC NAC in the treatment of 
HER2- primary breast cancer. Docetaxel was combined with cyclophosphamide 
Neoadjuvant chemotherapy, and hence, the results stated that TC NAC had 
exhibited little effective in breast cancer except for the triple-negative type. Patient 
of 20-70 yrs. of age having stage I,II, or III were taken for this study. Patients 
diagnosed with HER2-, N0–N1,invasive breast cancer were considered for this 
study. A dose of 75 mg/m2 docetaxel and 600 mg/m2 Cyclophosphamide for four 
cycles every three weeks were given to the patients with HER2- Breast cancer for 
investigating The efficacy and safety as well as tolerability of NAC combined with 
cyclophosphamide and Docetaxel which was the primary objective of this study. 
The study design used here was prospective, open-label, and nonrandomized, 
which took place in seven institutions. 4+9 out of 52 patient completed The 
treatment, which got to be 94.2 %. Then, it was discontinued in three patients 
due to it caused adverse reactions like grade 3 skin eruption, skin pain, grade 
4 leukopenia, and neutropenia. The mean dose intensity for docetaxel and 
cyclophosphamide were 24.3 and 192.3 mg/m2 per week, whereas the relative 
dose intensity of the same drugs were 97.1 and 96.2%. Combined therapy 
was seen effective the single drugs but still not every patient need them. This 
combined therapy was perceived as effective in the treatment of triple negative 
breast cancer (Nakatsukasa et al., 2016).
9. Physicians and Patient Barriers
In spite of having a vast number of breast cancer therapy for 
woman, there is a crucial barrier in it, and that is the lack of 
having confidence in recognizing worthy risk patients. Most 
of the time physicians have not used the gail model or risk 
assessment model (Corbelli et al., 2014), which is nowadays 
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the best tool available for spotting appropriate candidates 
or patients for preventative therapy. Among a survey of 300 
participants, only 33% of physicians using the gail model 
whereas, in the case of gynaecologists, it was 60%.
Not having good knowledge and inadequate training 
in risk assessment is the other factors of physicians that 
prevent them from using these tools. Different factors 
included are: the fear of having side effects, beliefs and 
knowledge regarding preventive therapy, uncertain between 
chemotherapy and chemoprevention, cost of treatment, 
and drug efficacy. Many women don’t take treatment or 
medicines thinking them as “unnatural” or necessarily not 
needed and reject taking them unless are told that it is 
essential for treatment and there are some people who are 
afraid of taking treatment (Holmberg et al., 2015). There 
are other factors also like age, income or employment status, 
no insurance, etc. that leads to not seeking treatment. 
Women having low income fear to take treatment due to the 
high cost. Barriers between patients and doctors are like the 
language barrier, decision making, and cultural differences.
Language barrier:- Difficulty in speaking the same 
language and understanding the same language is a 
significant barrier between patients and doctors. The 
solution for this can be any interpreters like neighbours 
their relatives, etc., but oncologist may not be satisfied 
that the information or explanation provided by him/her 
understandable by the patient or not. Even worse happens 
if there are no interpreters. Medical terminology is also a 
barrier even for those who understand physician’s language 
very well.
Cultural differences:- Cultural differences are there like 
physical activity and diet. Some patients may think that diet 
follow up is very general, and physical activity is too tough.
Treatment decision making:- Decision making depends 
on the patient or patient relatives. But, its physician 
responsibility to guide patients regarding therapy. There is a 
barrier of understanding for a patient that what physician is 
trying to say, this remains a question that is it beneficial to 
take the therapy or not.
In most cases, the patient of breast cancer is from 
developing countries in the most advanced stage of breast 
cancer. Barriers to use health care system is low maintained 
infrastructure, lack of information or missed information, 
economics, lack of resources. These are some points which 
delay the initial diagnosis process. Delay in diagnosis 
and treatment is related to various other barriers like age, 
education, place of living, low finance, no health insurance, 
work conditions and ethnic. In developing countries, because 
of fewer resources and low maintained infrastructure patient 
is not diagnosed early. Because of the lack of these services, 
detection of breast cancer in the early stages and treatment 
of breast becomes more expensive and more difficult. 
Sociocultural barriers are also there like women don’t have 
enough or no knowledge about the disease. 
Women having less knowledge, they cannot detect 
early symptoms of breast cancer. Lack of information 
regarding the disease delays health care. Early signs and 
symptoms are not recognized by the patient like nodules, 
oedema, and erythema, sometimes friends and family 
give a different meaning to these signs and symptoms 
and patient don’t take these symptoms seriously. Both less 
information or knowledge and socioeconomic myth lead to 
delay in the early diagnosis. First of all, there is a need to 
guide and educate women regarding breast cancer signs and 
symptom. Social myths are difficult to remove if once they 
are established, and these myths delay the early detection of 
disease, myths like cancer are deadly. Studies report show 
that fear of disease and lack of knowledge is a socioeconomic 
barrier. There are organizational barriers, no primary health 
care organization, and no organization regarding educating 
the females. The organizational barrier also creates a delay in 
detecting early symptoms in breast cancer - lack of patient 
counselling and lack of examinations with health care 
system or services. 
In developing countries or developed countries, there 
are a lot of people who are suffering from breast cancer, a 
long line of patients means a long time for waiting; this is 
also a barrier to assess health care to breast cancer. Ineffective 
management of the health care system, unorganized 
infrastructure, less investment in policies of attention because 
of these points, women are not getting timely treatment. 
Most of the women lived far from cancer hospital, so patient 
counselling, transportation cost, and examinations become 
a barrier in providing good health care to a breast cancer 
patient. The long waiting list can lead to gap between the 
end of chemotherapy and breast surgery and this gap can 
cause progression of the disease
Patients don’t stick to prescribed medications. A lot 
of patients fail to fulfill the initial prescription and fail to 
administer the drug regularly and cannot continue therapy 
on a long term basis. Discontinuation at a suboptimal 
therapeutic level can lead to treatment failure. Oncology 
has made a lot of efforts in developing effective treatments 
for increasing survival of cancer patients. Surprisingly 
adherence to prescription is a significant problem for 
medications such as chemotherapy and other life-saving 
drugs. Mostly used necessary treatment for breast cancer 
is hormonal therapy (adjuvant) for hormonal sensitive 
breast cancers, these oral agents are like tamoxifen and 
aromatase inhibitors, and these are prescribed for five 
years or longer. Nonetheless, surprisingly, breast cancer 
patients discontinue this therapy approximately seven to 
ten percent per year (hormonal therapy) (Hershman et al., 
2010).
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Conclusion
For any cancer to be diagnosed and treated successfully, 
proper plan is required to control it. The main target of the 
plan is to cure cancer patients or prolong their life, ensuring 
a better quality of life. For the effective diagnosis and 
treatment program, it must be linked to an early detection 
program, so that the patients can be treated at an early 
stage when there are higher chances of curing the disease. 
It also needs to be integrated with a palliative care program, 
so that patients with advanced cancers, who can no longer 
benefit from treatment, will get adequate relief from their 
physical, psychosocial and spiritual suffering. Moreover, 
awareness programs should be conducted to avoid various 
types of barriers such as patients related by educating the 
patients, family, and community members about the cancer 
risk factors and the preventive measures to prevent cancer. 
Though there are limited resources, diagnosis and treatment 
services should initially target all patients presenting with 
curable cancers that can be detected early. 
Now a days, women are facing geographical, 
organizational and health service barriers added by social, 
cultural and economic ones, affecting the search for health 
care after diagnosing the signs and symptoms of gross 
changes in the breast morphology and access to consultation 
with specialists, examinations for diagnosis and treatment. 
The fact noted made it need of hour to analyse the outcomes 
so as to overcome the obstacles and its consequences relating 
to health care in the breast cancer so that the most effective 
treatment can be provided to the patient. It is also useful for 
health managers and professionals, due to their involvement 
in attention to breast cancer since the early detection until 
the high complexity treatment.
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